Target Validation Information
TTD ID	T70067
Target Name	TRAIL receptor 2 (TRAIL-R2)
Type of Target	Clinical trial
Action against Disease Model	Conatumumab	Drug Info	Conat uM uMab binds to DR5, activating intracellular caspases in vitro in the presence of a cross-linker. Conat uM uMab has activity in vivo and inhibits t uMor growth in colon (Colo205 and HCT-15), lung (H2122) and pancreatic (MiaPaCa2/T2) xenograft models. Conat uM uMab also enhances the antit uMor activity of chemotherapeutics in vivo. Caspase activation in Colo205 t uMors is dose-dependent and correlated with ser uM concentrations of conat uM uMab. Increases in ser uM caspase-3/7 activity and levels of M30 (neoepitope of caspase-cleaved cytokeratin-18) are linked to activation of the extrinsic apoptotic pathway using conat uM uMab in a preclinical model.	[1]
References
REF 1	Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.